Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 76 out of 100. Getting a diagnosis

Topic: Risk, prevention and care in population studies

Plain-language summary

Background Observational epidemiological studies have shown a positive association between hypertension and risk of incident dementia; however, the effects of antihypertensive therapy on cognitive function in controlled trials have been conflicting, and meta-analyses of the trials have not provided clear evidence of whether antihypertensive treatment reduces dementia incidence. The Hypertension in the Very Elderly trial (HYVET) was designed to assess the risks and benefits of treatment of hypertension in elderly patients and included an assessment of cognitive function. Methods Patients with hypertension (systolic pressure 160-200 mm Hg; diastolic pressure Findings 3336 HYVET participants had at least one follow-up assessment (mean 2.2 years) and were included: 1687 participants were randomly assigned to the treatment group and 1649 to the placebo group. Only five reports of adverse effects were attributed to the medication: three in the placebo group and two in the treatment group. The mean decrease in systolic blood pressure between the treatment and placebo groups at 2 years was systolic -15 mm Hg, p Interpretation Antihypertensive treatment in elderly patients does not statistically reduce incidence of dementia. This negative finding might have been due to the short follow-up, owing to the early termination of the trial, or the modest effect of treatment. Nevertheless, the HYVET findings, when included in a meta-analysis, might support antihypertensive treatment to reduce incident dementia.

What this study adds

Evidence grade: High

This is a pooled review of 1,687 participants. Follow-up averaged only 2.2 years because the trial was stopped early, and the authors say the negative result "might have been due to the short follow-up… or the modest effect of treatment". They add that the findings, "when included in a meta-analysis, might support" blood-pressure treatment to reduce dementia.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., et al. (2008). Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(08)70143-1

Vancouver

Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. The Lancet. Neurology. 2008. doi:10.1016/s1474-4422(08)70143-1. PMID: 18614402.

BibTeX

@article{peters2008-18614402,
  author  = {Peters, R. and Beckett, N. and Forette, F. and Tuomilehto, J. and Clarke, R. and Ritchie, C. and Waldman, A. and Walton, I. and others},
  title   = {{Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial}},
  journal = {The Lancet. Neurology},
  year    = {2008},
  doi     = {10.1016/s1474-4422(08)70143-1},
  pmid    = {18614402},
  url     = {https://doi.org/10.1016/s1474-4422(08)70143-1}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this double-blind, placebo-controlled trial of 3,336 elderly people with high blood pressure (systolic 160–200 mm Hg), treatment lowered systolic pressure by 15 mm Hg more than placebo at 2 years, but the authors concluded it "does not statistically reduce incidence of dementia". Follow-up averaged only 2.2 years because the trial was stopped early, and the authors say the negative result "might have been due to the short follow-up… or the modest effect of treatment". They add that the findings, "when included in a meta-analysis, might support" blood-pressure treatment to reduce dementia.

Study details

How this study scored 76/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 4 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 76 of 100.76 of 100 points earned24 not earned

Published in a leading specialty journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (The Lancet. Neurology)
Journal's citation record 3 / 4 The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2008 — within 20 year(s) of the newest study here
Sample size 3 / 4 1,687 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 6 / 7 Cited 771 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 38.5 citations a year over 20 year(s) since 2008
Impact for its field and year 5 / 6 Cited 40.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 47 other studies in this library
Still being cited 2 / 4 Cited 49 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Christopher John Bulpitt: h-index 68 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Oxford: institution h-index 2,205 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 18614402)
Free to read 0 / 2 Behind a paywall — scores zero
Total 76 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

47 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →